Skip to Content

Circulating Tumor DNA: A New Approach to Cancer Monitoring

Cancer research is increasingly exploring ways to detect and monitor tumors through blood samples. One promising approach involves circulating tumor DNA (ctDNA), small DNA fragments released into the bloodstream by tumor cells. By analyzing these fragments, researchers can investigate tumor-associated genetic alterations without relying exclusively on tissue biopsies.

How Does Circulating Tumor DNA Work?

Tumor cells release DNA fragments into the bloodstream through processes that include cell death and other forms of DNA release. These fragments circulate alongside cell-free DNA originating from healthy tissues.

Liquid biopsy techniques analyze blood samples to identify tumor-associated mutations, copy-number alterations, and other molecular changes. Because ctDNA can represent genetic material from different tumor regions, it may provide information about tumor heterogeneity.

Applications in Cancer Research

Researchers are investigating ctDNA for several applications:

  • Treatment monitoring: Tracking changes in ctDNA levels during therapy.

  • Minimal residual disease: Detecting molecular evidence of remaining cancer after treatment.

  • Resistance monitoring: Identifying genetic alterations associated with treatment resistance.

  • Tumor profiling: Investigating tumor-associated mutations when tissue samples are limited.

However, ctDNA detection depends on factors such as tumor type, disease stage, DNA concentration, and assay sensitivity. A negative result does not necessarily mean that cancer is absent.

New Technologies and Challenges

Next-generation sequencing and highly sensitive molecular assays are improving the detection of rare tumor-derived DNA fragments. Researchers are also developing computational methods to distinguish cancer-associated mutations from background variation, including mutations arising from clonal hematopoiesis.

Despite these advances, liquid biopsy performance varies across clinical applications, and results must be interpreted alongside other clinical information.

Conclusion

Circulating tumor DNA connects molecular genetics, cancer biology, and precision medicine. Continued advances in sequencing technologies and computational analysis may